Merck’s Patent Win Over Gilead Reversed Over False Testimony

Updated on
  • Judge throws out $200 million jury verdict in hepatitis C case
  • Gilead’s Harvoni, Sovaldi drugs dominate market for treatment

Merck & Co.’s $200 million jury verdict against Gilead Sciences Inc. was voided in a patent dispute over a breakthrough for hepatitis C because of misconduct by a witness at the companies’ trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.